Cercar
01/02/2023
BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis
Fusta-Novell, X, Garcia-Herrera, A, Yelamos, O. BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis. Actas Dermo-Sifiliograficas. 2023; 114(2)DOI:10.1016/j.ad.2021.10.022. PMID:36216154. IF:(Q/D).
01/01/2023
Bimekizumab in the Treatment of Plaque Psoriasis Focus on Patient Selection and Perspectives
Camina-Conforto, G, Mateu-Arrom L., López-Ferrer A., Puig L.. Bimekizumab in the Treatment of Plaque Psoriasis Focus on Patient Selection and Perspectives. Patient Preference and Adherence. 2023; 17DOI:10.2147/PPA.S350760. PMID:37408843. IF:2.000(Q2/4D).
01/01/2023
Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain
Artime E., Serra E., Mert C., Díaz-Cerezo S., Huete T., Hernández-Subirá I., Lledo-Bryant L., Sicras-Mainar A.. Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain. Actas Dermo-Sifiliograficas. 2023; 114(1)DOI:10.1016/j.ad.2022.08.025. PMID:36368579. IF:(Q/D).
01/01/2023
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Strober B., Paul C., Blauvelt A., Thaçi D., Puig L., Lebwohl M., White K., Vanvoorden V., Deherder D., Gomez N.N., Eyerich K.. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 89(3)DOI:10.1016/j.jaad.2023.04.063. PMID:37182701. IF:12.800(Q1/1D).
01/01/2023
PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries
Langenbruch A., Mohr N., Andrees V., Kessens I., Reich A., Czarnecka-Operacz M., Puig L., Dauden E., Iversen L., Augustin M.. PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries. ACTA DERMATO-VENEREOLOGICA. 2023; 103DOI:10.2340/actadv.v103.6532. PMID:37649411. IF:3.500(Q1/3D).
01/01/2023
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results
Pereyra-Rodríguez J.-J., Herranz P., Ruiz-Villaverde R., Elosua-González M., Galán-Gutiérrez M., Figueras-Nart I., Miquel J., de la Cueva P., Serra-Baldrich E., Munera-Campos M., Melé-Ninot G., Expósito-Serrano V., Perez B., Serrano A., Ortiz de Frutos J.F., Armario-Hita J.C.. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2023; 48(9)DOI:10.1093/ced/llad153. PMID:37098171. IF:3.700(Q1/2D).